Cantor Fitzgerald Comments on AVITA Medical FY2025 Earnings

AVITA Medical, Inc. (NASDAQ:RCEL - Free Report) - Analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for AVITA Medical in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.99) per share for the year, up from their previous forecast of ($1.01). The consensus estimate for AVITA Medical's current full-year earnings is ($0.95) per share.

Separately, D. Boral Capital reiterated a "buy" rating and set a $22.00 price target on shares of AVITA Medical in a research note on Thursday, April 10th.

AVITA Medical Trading Down 3.3%

NASDAQ:RCEL opened at $7.01 on Wednesday. AVITA Medical has a 12 month low of $6.60 and a 12 month high of $14.16. The company has a current ratio of 2.83, a quick ratio of 2.47 and a debt-to-equity ratio of 9.39. The firm's 50 day moving average is $8.81 and its 200 day moving average is $10.23. The stock has a market capitalization of $185.31 million, a PE ratio of -2.93 and a beta of 1.74.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.14). The business had revenue of $18.51 million for the quarter, compared to the consensus estimate of $33.15 million. AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RCEL. AlphaQuest LLC boosted its position in shares of AVITA Medical by 24.7% in the fourth quarter. AlphaQuest LLC now owns 9,378 shares of the company's stock valued at $120,000 after acquiring an additional 1,858 shares during the period. Bank of New York Mellon Corp increased its stake in AVITA Medical by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 55,141 shares of the company's stock worth $449,000 after acquiring an additional 1,924 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of AVITA Medical by 48.0% during the 4th quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company's stock valued at $92,000 after acquiring an additional 2,324 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of AVITA Medical by 16.4% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 18,181 shares of the company's stock valued at $148,000 after acquiring an additional 2,564 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in shares of AVITA Medical in the fourth quarter worth approximately $38,000. Institutional investors own 27.66% of the company's stock.

Insider Buying and Selling at AVITA Medical

In related news, Director Robert Mcnamara acquired 10,000 shares of the firm's stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $10.09 per share, for a total transaction of $100,900.00. Following the purchase, the director now owns 45,749 shares in the company, valued at $461,607.41. This trade represents a 27.97% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.82% of the company's stock.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.